Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Nab-Paclitaxel Plus Carboplatin or Gemcitabine vs Gemcitabine Plus Carboplatin as First-Line Treatment for Patients With Triple-Negative Metastatic Breast Cancer: Results From the tnAcity TrialAnn. Oncol 2018 Jun 06;[EPub Ahead of Print], DA Yardley, R Coleman, P Conte, J Cortes, A Brufsky, M Shtivelband, R Young, C Bengala, H Ali, J Eakel, A Schneeweiss, L de la Cruz-Merino, S Wilks, J O'Shaughnessy, S Glück, H Li, J Miller, D Barton, N Harbeck
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.